{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:49:42Z","timestamp":1794048582053,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":64,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005971","name":"Deutsche Herzstiftung","doi-asserted-by":"publisher","award":["S\/02\/24"],"award-info":[{"award-number":["S\/02\/24"]}],"id":[{"id":"10.13039\/501100005971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005971","name":"Deutsche Herzstiftung","doi-asserted-by":"publisher","award":["SRF-HF\/24"],"award-info":[{"award-number":["SRF-HF\/24"]}],"id":[{"id":"10.13039\/501100005971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01-HL141505"],"award-info":[{"award-number":["R01-HL141505"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AR080194"],"award-info":[{"award-number":["R01-AR080194"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01-HL141505"],"award-info":[{"award-number":["R01-HL141505"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cardiovascular outcome trials of the incretin-based medicines tirzepatide and semaglutide have shown benefits in populations with varying levels of cardiovascular risk. However, without direct head-to-head comparisons, treatment decisions rely on indirect evidence from heterogeneous trial populations, leaving optimal treatment choices uncertain. Here we conducted five cohort studies to assess the effectiveness of tirzepatide and semaglutide in patients with elevated cardiovascular risk, including obesity and type 2 diabetes, enrolled in insurance programs in the USA between 2018 and 2025. First, we emulated two cardiovascular outcome trials, SUSTAIN-6 (semaglutide versus sitagliptin as placebo proxy) and SURPASS-CVOT (tirzepatide versus dulaglutide), to benchmark and critically evaluate our design, data and analytic framework. Second, we assessed each drug in expanded populations reflective of patients routinely seen in clinical practice. Third, we directly compared tirzepatide versus semaglutide. Baseline confounders were balanced using propensity score matching. For the primary composite endpoint of myocardial infarction, stroke or all-cause mortality, benchmarking identified high agreement between the reference trials and their emulations for all individual endpoints except for all-cause mortality in SUSTAIN-6, informing subsequent analyses. In expanded populations, comparing semaglutide versus sitagliptin for the composite outcome of myocardial infarction or stroke yielded a hazard ratio of 0.82 (95% confidence interval (CI) 0.74 to 0.91), and comparing tirzepatide versus dulaglutide for the composite outcome including mortality yielded a hazard ratio of 0.87 (95% CI 0.75 to 1.01). In the head-to-head comparison of tirzepatide versus semaglutide, the hazard ratio was 1.06 (95% CI 0.95 to 1.18). These findings support a comparable cardiovascular benefit of tirzepatide and semaglutide in clinical practice and demonstrate how rigorously designed real-world evidence can complement randomized clinical trials. ClinicalTrials.gov registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT06659744\" ext-link-type=\"uri\">NCT06659744<\/jats:ext-link>\n                    ,\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT07088718\" ext-link-type=\"uri\">NCT07088718<\/jats:ext-link>\n                    ,\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT07096063\" ext-link-type=\"uri\">NCT07096063<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-025-04102-x","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T21:01:42Z","timestamp":1762722102000},"page":"342-352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3190-0462","authenticated-orcid":false,"given":"Nils","family":"Kr\u00fcger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0299-7273","authenticated-orcid":false,"given":"Rishi J.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9182-304X","authenticated-orcid":false,"given":"Sushama Kattinakere","family":"Sreedhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna R.","family":"Kehoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshiro","family":"Fuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6428-3001","authenticated-orcid":false,"given":"Heribert","family":"Schunkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7761-7090","authenticated-orcid":false,"given":"Shirley V.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,9]]},"reference":[{"key":"4102_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa2415879","volume":"393","author":"C Magnussen","year":"2025","unstructured":"Magnussen, C., Alegre-Diaz, J., Al-Nasser, L. & Blankenberg, S. Global effect of cardiovascular risk factors on lifetime estimates. N. Engl. J. Med. 393, 125\u2013138 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4102_CR2","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1016\/S0140-6736(24)01548-4","volume":"404","author":"M Ng","year":"2024","unstructured":"Ng, M. et al. National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990\u20132021, and forecasts up to 2050. Lancet 404, 2278\u20132298 (2024).","journal-title":"Lancet"},{"key":"4102_CR3","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","volume":"381","author":"ZJ Ward","year":"2019","unstructured":"Ward, Z. J. et al. Projected US state-level prevalence of adult obesity and severe obesity. N. Engl. J. Med. 381, 2440\u20132450 (2019).","journal-title":"N. Engl. J. Med."},{"key":"4102_CR4","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1001\/jama.2025.2704","volume":"333","author":"EK Aryee","year":"2025","unstructured":"Aryee, E. K., Zhang, S., Selvin, E. & Fang, M. Prevalence of obesity with and without confirmation of excess adiposity among US adults. JAMA 333, 1726\u20131728 (2025).","journal-title":"JAMA"},{"key":"4102_CR5","doi-asserted-by":"publisher","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","volume":"145","author":"JJ Joseph","year":"2022","unstructured":"Joseph, J. J. et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation 145, e722\u2013e759 (2022).","journal-title":"Circulation"},{"key":"4102_CR6","doi-asserted-by":"publisher","unstructured":"Powell-Wiley, T. M. et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation https:\/\/doi.org\/10.1161\/CIR.0000000000000973 (2021).","DOI":"10.1161\/CIR.0000000000000973"},{"key":"4102_CR7","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4102_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"4102_CR9","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman, R. R. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 377, 1228\u20131239 (2017).","journal-title":"N. Engl. J. Med."},{"key":"4102_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121\u2013130 (2019).","journal-title":"Lancet"},{"key":"4102_CR11","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834\u20131844 (2016).","journal-title":"N. Engl. J. Med."},{"key":"4102_CR12","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain, M. et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 381, 841\u2013851 (2019).","journal-title":"N. Engl. J. Med."},{"key":"4102_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne, L. J. et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N. Engl. J. Med. 393, 26\u201336 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4102_CR14","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/ANNALS-24-02870","volume":"178","author":"JW Ostrominski","year":"2025","unstructured":"Ostrominski, J. W. et al. Trends in utilization of glucose- and weight-lowering medications after tirzepatide approval in the United States: a population-based cohort study. Ann. Intern. Med. 178, 620\u2013633 (2025).","journal-title":"Ann. Intern. Med."},{"key":"4102_CR15","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas, J. P. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 385, 503\u2013515 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4102_CR16","unstructured":"Lilly\u2019s Mounjaro (Tirzepatide), a GIP\/GLP-1 Dual Agonist, Demonstrated Cardiovascular Protection in Landmark Head-to-Head Trial, Reinforcing Its Benefit in Patients with Type 2 Diabetes and Heart Disease (Eli Lilly and Company, accessed 19 August 2025); https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-mounjaro-tirzepatide-gipglp-1-dual-agonist-demonstrated"},{"key":"4102_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","volume":"267","author":"SJ Nicholls","year":"2024","unstructured":"Nicholls, S. J. et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am. Heart J. 267, 1\u201311 (2024).","journal-title":"Am. Heart J."},{"key":"4102_CR18","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/cpt.3621","volume":"117","author":"SV Wang","year":"2025","unstructured":"Wang, S. V. et al. A benchmark, expand, and calibration (BenchExCal) trial emulation approach for using real-world evidence to support indication expansions: design and process for a planned empirical evaluation. Clin. Pharmacol. Ther. 117, 1820\u20131828 (2025).","journal-title":"Clin. Pharmacol. Ther."},{"key":"4102_CR19","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1161\/CIRCULATIONAHA.125.073235","volume":"151","author":"S Schneeweiss","year":"2025","unstructured":"Schneeweiss, S. & Kr\u00fcger, N. Non-randomized database analyses to complement randomized clinical trials: promising approaches for cardiovascular medicine. Circulation 151, 1495\u20131497 (2025).","journal-title":"Circulation"},{"key":"4102_CR20","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1001\/jama.2023.4221","volume":"329","author":"SV Wang","year":"2023","unstructured":"Wang, S. V. et al. Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials. JAMA 329, 1376\u20131385 (2023).","journal-title":"JAMA"},{"key":"4102_CR21","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/cpt.1633","volume":"107","author":"JM Franklin","year":"2020","unstructured":"Franklin, J. M. et al. Nonrandomized real-world evidence to support regulatory decision making: process for a randomized trial replication project. Clin. Pharmacol. Ther. 107, 817\u2013826 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"key":"4102_CR22","doi-asserted-by":"crossref","unstructured":"Kr\u00fcger, N. et al. Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction. JAMA 334, 1255\u20131266 (2025).","DOI":"10.1001\/jama.2025.14092"},{"key":"4102_CR23","doi-asserted-by":"publisher","unstructured":"Willard, F. S. et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.140532 (2020).","DOI":"10.1172\/jci.insight.140532"},{"key":"4102_CR24","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.2337\/db25-0393","volume":"74","author":"JE Campbell","year":"2025","unstructured":"Campbell, J. E. & Drucker, D. J. Therapeutic targeting of the GIP receptor\u2014revisiting the controversies. Diabetes 74, 1320\u20131325 (2025).","journal-title":"Diabetes"},{"key":"4102_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","volume":"19","author":"R Hammoud","year":"2023","unstructured":"Hammoud, R. & Drucker, D. J. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat. Rev. Endocrinol. 19, 201\u2013216 (2023).","journal-title":"Nat. Rev. Endocrinol."},{"key":"4102_CR26","doi-asserted-by":"publisher","unstructured":"Drucker, D. J. Expanding applications of therapies based on GLP1. Nat. Rev. Endocrinol. https:\/\/doi.org\/10.1038\/s41574-024-01066-9 (2024).","DOI":"10.1038\/s41574-024-01066-9"},{"key":"4102_CR27","doi-asserted-by":"publisher","first-page":"R211","DOI":"10.1530\/EJE-19-0566","volume":"181","author":"MA Nauck","year":"2019","unstructured":"Nauck, M. A. & Meier, J. J. Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes?. Eur. J. Endocrinol. 181, R211\u2013R234 (2019).","journal-title":"Eur. J. Endocrinol."},{"key":"4102_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13300-024-01684-6","volume":"16","author":"R Mody","year":"2025","unstructured":"Mody, R. et al. Characteristics and dosing patterns of tirzepatide users with type 2 diabetes in the United States. Diabetes Ther. 16, 307\u2013327 (2025).","journal-title":"Diabetes Ther."},{"key":"4102_CR29","doi-asserted-by":"publisher","unstructured":"Di Muro, F. M. et al. Preserving and promoting clinical trial representativeness: a review of existing strategies and the path forward. JAMA Cardiol. https:\/\/doi.org\/10.1001\/jamacardio.2025.2421 (2025).","DOI":"10.1001\/jamacardio.2025.2421"},{"key":"4102_CR30","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/clpt.2010.233","volume":"88","author":"R Temple","year":"2010","unstructured":"Temple, R. Enrichment of clinical study populations. Clin. Pharmacol. Ther. 88, 774\u2013778 (2010).","journal-title":"Clin. Pharmacol. Ther."},{"key":"4102_CR31","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1038\/s41591-024-03273-3","volume":"30","author":"F Zannad","year":"2024","unstructured":"Zannad, F. et al. How to make cardiology clinical trials more inclusive. Nat. Med. 30, 2745\u20132755 (2024).","journal-title":"Nat. Med."},{"key":"4102_CR32","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1161\/CIRCULATIONAHA.120.051718","volume":"143","author":"JM Franklin","year":"2021","unstructured":"Franklin, J. M. et al. Emulating randomized clinical trials with nonrandomized real-world evidence studies. Circulation 143, 1002\u20131013 (2021).","journal-title":"Circulation"},{"key":"4102_CR33","doi-asserted-by":"publisher","unstructured":"Melson, E., Ashraf, U., Papamargaritis, D. & Davies, M. J. What is the pipeline for future medications for obesity? Int. J. Obes. https:\/\/doi.org\/10.1038\/s41366-024-01473-y (2024).","DOI":"10.1038\/s41366-024-01473-y"},{"key":"4102_CR34","doi-asserted-by":"publisher","unstructured":"Makary, M. A. & Prasad, V. Priorities for a new FDA. JAMA https:\/\/doi.org\/10.1001\/jama.2025.10116 (2025).","DOI":"10.1001\/jama.2025.10116"},{"key":"4102_CR35","doi-asserted-by":"publisher","first-page":"e009078","DOI":"10.1161\/CIRCOUTCOMES.122.009078","volume":"16","author":"BA Bates","year":"2023","unstructured":"Bates, B. A. et al. Validity of International Classification of Diseases (ICD)-10 diagnosis codes for identification of acute heart failure hospitalization and heart failure with reduced versus preserved ejection fraction in a national Medicare sample. Circ. Cardiovasc. Qual. Outcomes 16, e009078 (2023).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"4102_CR36","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016906","volume":"9","author":"RJ Desai","year":"2020","unstructured":"Desai, R. J., Levin, R., Lin, K. J. & Patorno, E. Bias implications of outcome misclassification in observational studies evaluating association between treatments and all-cause or cardiovascular mortality using administrative claims. J. Am. Heart Assoc. 9, e016906 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"4102_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ahj.2004.02.013","volume":"148","author":"Y Kiyota","year":"2004","unstructured":"Kiyota, Y. et al. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am. Heart J. 148, 99\u2013104 (2004).","journal-title":"Am. Heart J."},{"key":"4102_CR38","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/pds.2312","volume":"21","author":"SE Andrade","year":"2012","unstructured":"Andrade, S. E. et al. A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol. Drug Saf. 21, 100\u2013128 (2012).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"4102_CR39","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/pds.1518","volume":"17","author":"CL Roumie","year":"2008","unstructured":"Roumie, C. L. et al. Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data. Pharmacoepidemiol. Drug Saf. 17, 20\u201326 (2008).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"4102_CR40","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/pds.1924","volume":"19","author":"PM Wahl","year":"2010","unstructured":"Wahl, P. M. et al. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol. Drug Saf. 19, 596\u2013603 (2010).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"4102_CR41","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green, J. B. et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 373, 232\u2013242 (2015).","journal-title":"N. Engl. J. Med."},{"key":"4102_CR42","doi-asserted-by":"publisher","unstructured":"Cashin, A. G. et al. Transparent reporting of observational studies emulating a target trial\u2014the TARGET statement. JAMA https:\/\/doi.org\/10.1001\/jama.2025.13350 (2025).","DOI":"10.1001\/jama.2025.13350"},{"key":"4102_CR43","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1001\/jama.2024.2988","volume":"331","author":"SV Wang","year":"2024","unstructured":"Wang, S. V. & Schneeweiss, S. Data checks before registering study protocols for health care database analyses. JAMA 331, 1445\u20131446 (2024).","journal-title":"JAMA"},{"key":"4102_CR44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/pds.5507","volume":"32","author":"SV Wang","year":"2023","unstructured":"Wang, S. V. et al. HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: a good practices report of a joint ISPE\/ISPOR task force. Pharmacoepidemiol. Drug Saf. 32, 44\u201355 (2023).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"4102_CR45","doi-asserted-by":"publisher","first-page":"k3532","DOI":"10.1136\/bmj.k3532","volume":"363","author":"SM Langan","year":"2018","unstructured":"Langan, S. M. et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). Br. Med. J. 363, k3532 (2018).","journal-title":"Br. Med. J."},{"key":"4102_CR46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund, J. L., Richardson, D. B. & St\u00fcrmer, T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr. Epidemiol. Rep. 2, 221\u2013228 (2015).","journal-title":"Curr. Epidemiol. Rep."},{"key":"4102_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70048","volume":"33","author":"QL Her","year":"2024","unstructured":"Her, Q. L., Rouette, J., Young, J. C., Webster-Clark, M. & Tazare, J. Core concepts in pharmacoepidemiology: new-user designs. Pharmacoepidemiol. Drug Saf. 33, e70048 (2024).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"4102_CR48","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","volume":"330","author":"M Sodhi","year":"2023","unstructured":"Sodhi, M., Rezaeianzadeh, R., Kezouh, A. & Etminan, M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA 330, 1795\u20131797 (2023).","journal-title":"JAMA"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04102-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04102-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04102-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:03:03Z","timestamp":1769007783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04102-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,9]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4102"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04102-x","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,9]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.S. reports personal fees from Aetion Inc., a software-enabled analytics company, and grants from Bayer, UCB and Boehringer Ingelheim to Brigham and Women\u2019s Hospital outside the submitted work. H.S. reports personal fees from AstraZeneca, Bayer Vital GmbH, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, MSD, Novartis, Pharmacosmos, Sanofi, Servier, Synlab, Amgen and Amarin outside the submitted work. S.V.W. reports personal fees from MITRE, a federally funded research and development center for the Centers for Medicare and Medicaid Services and personal fees from Cytel Inc. during the conduct of the study. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}